Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cutaneous adverse events associated with long-term immunomodulating therapy in multiple sclerosis ; volume:9 ; number:2 ; day:23 ; month:11 ; year:2011 ; pages:1 ; date:12.2011
Journal of translational medicine ; 9, Heft 2 (23.11.2011), 1, 12.2011
- Urheber
-
Balak, Deepak MW
- Beteiligte Personen und Organisationen
-
Hengstman, Gerald JD
Hupperts, Raymond
Thio, H Bing
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-9-S2-P14
- URN
-
urn:nbn:de:1111-2016041439268
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Balak, Deepak MW
- Hengstman, Gerald JD
- Hupperts, Raymond
- Thio, H Bing
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients
Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients
Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis
Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events
Adverse cutaneous drug eruptions : 34 tables
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients
Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
Juvenile Dermatomyositis and Diffuse Cutaneous Systemic Sclerosis Overlap
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality